Chimeric antigen receptor-engineered dendritic cells incorporating endocytic receptor intracellular domains prime T cells and suppress tumor growth in preclinical mouse models, according to a study published in Nature Immunology. While dendritic cells serve as central orchestrators of antitumor immunity, their therapeutic effectiveness in solid tumors has been limited by cellular dysfunction and inadequate activation. To address these constraints, researchers engineered chimeric antigen receptor dendritic cells, or CAR-DCs, using specific intracellular signaling domains to enhance dendritic cell activity and reprogram the immunosuppressive tumor microenvironment.
The investigators identified the intracellular domains of the endocytic receptors CLEC9A and LY75, also known as DEC205, as essential elements for functional CAR-DC activity. Incorporating the intracellular domains of CLEC9A or DEC205 into CAR constructs triggered spleen tyrosine kinase phosphorylation and initiated downstream intracellular signaling. This signaling cascade promoted cellular uptake of antigens and enhanced antigen cross-presentation, which subsequently drove the expansion and functional activation of T cells.
In vivo evaluations across conventional and humanized mouse models demonstrated that CAR-DC administration suppressed solid tumor growth. The engineered dendritic cells promoted the expansion of tumor-reactive T cells, cross-presenting tumor antigens to stimulate CD8-positive T cell-mediated tumor killing. The treatment altered cell-to-cell interactions, remodeled the surrounding tumor microenvironment, and maintained a favorable preclinical safety profile in the tested animal models.
The authors also demonstrated that human HER2-targeted DEC205 and CLEC9A CAR-DCs mediated effective antitumor responses in experimental models. Based on these observations in cell and animal systems, the authors concluded that CAR-DCs provide a scalable and clinically translatable platform for solid tumor immunotherapy, though clinical benefits in human patients remain to be investigated in future clinical trials.
Subject of Research: Chimeric antigen receptor-engineered dendritic cells for solid tumor immunotherapy
Article Title: Rewiring dendritic cell function with CLEC9A and DEC205 CARs
Article References: Niu, C., Dai, X., Gao, H., Zhang, H., Ma, Y., Wang, H., Xiao, Z., Xu, Y., He, S., Ye, Z., Tang, X., Lin, P., Li, K., Pittet, M. J., Zhang, L., & Wang, C. (2026). Rewiring dendritic cell function with CLEC9A and DEC205 CARs. Nature Immunology. https://doi.org/10.1038/s41590-026-02711-3
Image Credits: AI Generated
DOI: 10.1038/s41590-026-02711-3
Keywords: dendritic cells, chimeric antigen receptors, CAR-DCs, CLEC9A, DEC205, LY75, SYK phosphorylation, antigen cross-presentation, CD8+ T cells, tumor microenvironment, solid tumors, humanized mice, HER2, cancer immunotherapy, T cell proliferation, antitumor immunity
News Source: Nathaniel Bowman. (November 13, 2026). Engineered CAR Dendritic Cells Suppress Tumor Growth in Mouse Models. Scienmag.



